Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cross-cultural Validation of a Screening Scale for the Misuse of Opioid Analgesics in Primary Care (VAMOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05431985
Recruitment Status : Completed
First Posted : June 24, 2022
Last Update Posted : June 24, 2022
Sponsor:
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand

Brief Summary:

Objective: Analgesic Opioids misuse among patients with chronic pain ranges from 0% to 50%. The general practitioner is the first prescriber of opioid analgesics Our objective was to validate in primary care the POMI (Prescription Opioid Misuse Index) to identify the misuse of AOs.

Study Setting: Patients with chronic pain, taking AOs for at least 3 months, and followed in general practice.

Study design: Psychometric study

Data Collection/Extraction methods: Eligible patients followed in general practice responded to the POMI: Test phase. They then responded after 2 weeks: the retest. The gold standard used was the DSM-V.


Condition or disease
Chronic Pain Addiction Opiate

Detailed Description:

Chronic pain represents a major problem in terms of individual, quality of life, and collective impact: cost generated by delays in treatment and care. The prevalence of chronic pain among the general population varies from 10.1 to 55.2%. In the front line, general practitioners (GP) are at the heart of treating pain : pain represent 43% of the reasons for the consultation, 24% of these being for chronic pain. More than half of these patients had exclusive care through their GP. The others are followed up in a pain assessment and treatment center.

In 2015, nearly one in five French people (17,1%) of French people have taken opioid treatment. The risk of opioid use disorder secondary to opioid analgesics among patients suffering from chronic pain varies from 0% to 50%. American recommendations advocate periodic surveillance of this opioid use disorder depending on the patient's risk factors, when chronic opioid analgesics are prescribed. The French "Limoges" recommendations also mention a systematic search for signs of psychological dependence during treatment and state that treatment with strong opioids should be stopped in the event of misuse, abuse or addiction. They recommend, on each examination, the investigation for signs of misuse or psychological dependence (characterised by craving) as ways of monitoring that strong opioids are being correctly used in chronic osteo-articular pain.

Identifying the misuse is a way of optimising their benefit/risk ratio

The difficulty in establishing the prevalence of misuse is due to a lack of standardization of studies and the lack of consensus in the use of assessment tools. Several tools are available internationally. The only diagnostic criteria available are those of the DSM-5 (Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders) or the ICD-10 which overestimate this prevalence notably by the presence of frequent tolerance and withdrawal criteria for these patients, in the absence of misuse or addiction. Today, no screening scale has been validated in France for primary care, but recently, the authors have validated the POMI scale in French to screen the patients specifically followed in pain clinic and presenting a misuse behavior of their opioid analgesic treatment. In 2015, treatment initiation was carried out by a GP in 59.1% of cases for weak opioid and 62.9% of cases for strong opioids and by a hospital doctor for 20.1% and 21% respectively7. Currently, no scale was validated in primary care. A scale validated in French would make it possible to standardize these screening practices and secure prescription both from the point of view of the doctor and of the patient. Furthermore, this absence of a validated tool in French is proving to be an obstacle to the development of true pharmaco-epidemiological studies on the prevalence of the opioids misuse. The originality of this study is to assess the clinical relevance of the french transcultural validation of the POMI scale in primary care in order to ensure an appropriate and relevant use by all health professionals and to allow large-scale screening for the misuse behavior of analgesic opioids.

The aim of the study was a validation of the French version of the Prescription Opioid Misuse Index - POMI patients with chronic pain in general practitioners setting.

Secondary objective

  • To study the profile of participants with misuse of opioid analgesics.
  • To compare the results of this study with the previous study on patients followed in pain clinic.

Layout table for study information
Study Type : Observational
Actual Enrollment : 160 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Cross-cultural Validation of a Screening Scale for the Misuse of Opioid Analgesics in Primary Care
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : March 1, 2019
Actual Study Completion Date : July 1, 2019





Primary Outcome Measures :
  1. Prescription Opioid Misuse Index - POMI [ Time Frame: at inclusion ]
    Prescription Opioid Misuse Index (POMI) scale was developed in the United States to assess the oxycodone misuse. This scale was validated among 137 subjects recruited from pain clinics, addiction treatment programs, jails, or private medical practice. The POMI is an 8 point self-assessment scale each numbered 0 (absence) or 1 (presence). The sum of point is used to calculate a score (between 0 and 8) and a score of more or equal to 2 is considered as positive and describe a misuse.

  2. Prescription Opioid Misuse Index - POMI [ Time Frame: 2 weeks after the first completion ]
    Prescription Opioid Misuse Index (POMI) scale was developed in the United States to assess the oxycodone misuse. This scale was validated among 137 subjects recruited from pain clinics, addiction treatment programs, jails, or private medical practice. The POMI is an 8 point self-assessment scale each numbered 0 (absence) or 1 (presence). The sum of point is used to calculate a score (between 0 and 8) and a score of more or equal to 2 is considered as positive and describe a misuse.


Secondary Outcome Measures :
  1. Sociodemographic characteristics [ Time Frame: once, at inclusion ]
    GPs asked patients about sociodemographic data (age, gender, family status, professional status); medical and family medical history; history of psychiatric problem, substance use and abuse.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults patients with chronic pain for at least 6 months, and with a prescription from the general practitioners of at least one opioid analgesic drug taken daily for at least the previous 3 months.
Criteria

Inclusion Criteria:

  • Patients aged 18 and over,
  • Patients with chronic pain for at least 6 months,
  • Patients with a prescription from the GP of at least one Opioid analgesic drug taken daily for at least the previous 3 months,
  • Patients registered with the French insurance system.

Exclusion Criteria:

  • Discontinuation of opioid prescriptions on the test phase day (no Retest possible),
  • Patients in the process of withdrawal (risk of having been withdrawn during the Retest phase),
  • Patients unable to complete the questionnaire alone,
  • Patients who are monitored by a pain clinic or addiction centre,
  • Patients with ongoing cancer,
  • Patients refusing to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05431985


Locations
Layout table for location information
France
CHU Clermont-Ferrand, UMR INSERM 1107, NEURO-DOL
Clermont-Ferrand, France
Département de médecine Générale, Facultés de Médecine de Clermont-Ferrand
Clermont-Ferrand, France
Département de médecine générale, Lyon
Lyon, France
Département de médecine générale, Faculté de médecine, Montpellier
Montpellier, France
Département de médecine générale, Faculté de médecine, Toulouse
Toulouse, France
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Layout table for additonal information
Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT05431985    
Other Study ID Numbers: 2015 LAPORTE
First Posted: June 24, 2022    Key Record Dates
Last Update Posted: June 24, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Clermont-Ferrand:
chronic pain
opioids
primary care
misuse
addiction
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Behavior, Addictive
Pain
Neurologic Manifestations
Compulsive Behavior
Impulsive Behavior